Sagimet Biosciences Inc. (SGMT)
3.45
-0.26 (-7.13%)
At close: Mar 03, 2025, 3:59 PM
3.51
1.68%
After-hours: Mar 03, 2025, 05:31 PM EST
Company Description
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways.
Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne.
The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers.
The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019.
Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Sagimet Biosciences Inc.
| Country | United States |
| IPO Date | Jul 17, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | David A. Happel |
Contact Details
Address: 155 Bovet Road San Mateo, California United States | |
| Website | https://sagimet.com |
Stock Details
| Ticker Symbol | SGMT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001400118 |
| CUSIP Number | 786700104 |
| ISIN Number | US7867001049 |
| Employer ID | 20-5991472 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David A. Happel | Chief Executive Officer, President & Director |
| Thierry Chauche | Chief Financial Officer & Principal Accounting Officer |
| Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D. | Chief Medical Officer |
| Dr. George W. Kemble Ph.D. | Executive Chairman of the Board |
| Dr. Lucas Pelkmans Ph.D. | Co-Founder |
| Dr. Marie O'Farrell Ph.D. | Senior Vice President of Research & Development |
| Elizabeth Rozek Esq., J.D. | General Counsel & Chief Compliance Officer |
| Robert D'Urso | Senior Vice President of New Products |
| Urs Greber Ph.D. | Co-Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 14, 2025 | 8-K | Current Report |
| Feb 07, 2025 | 4 | Filing |
| Feb 07, 2025 | 4 | Filing |
| Feb 07, 2025 | 4 | Filing |
| Feb 07, 2025 | 4 | Filing |
| Jan 02, 2025 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |